Literature DB >> 23537065

X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?

Sid Topiol1.   

Abstract

INTRODUCTION: In 2007, the X-ray structural determination of non-rhodopsin G-Protein coupled receptors (GPCRs), considered the most extensively targeted protein class for marketed drugs, commenced. With the relatively rapid availability of additional structures, an assessment of the progression made is needed in addition to the assessment of the understandings gleaned, deployment successes and forthcoming prospects. AREAS COVERED: The author reviews the approaches and tools that have made it possible to determine the three dimensional structures of GPCRs using X-ray crystallography. Furthermore, the author describes the methods suited for crystallization of membrane bound GPCR proteins including the lipidic cubic phase and various protein modification approaches. The author also provides highlights, from the literature, of the structures determined to date including targets solved, the nature of the content provided (such as selectivity, activating vs. inactivating determinants) and how these structural features relate to drug design strategies. EXPERT OPINION: The GPCR X-ray structures that have been so far determined have yielded significant information. This has presented dramatic evidence concerning their ability to impact the discovery of compounds through their action as traditional, orthosteric modulators. It is, however, noted that more challenging design strategies, such as identifying biased agonists and the use of sites remote from the orthosteric site for allosteric modulation, are still in their infancy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23537065     DOI: 10.1517/17460441.2013.783815

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  4 in total

1.  Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.

Authors:  Pankaj Pandey; Kuldeep K Roy; Robert J Doerksen
Journal:  J Biomol Struct Dyn       Date:  2019-02-05

Review 2.  Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.

Authors:  David R Janero; Ganesh A Thakur
Journal:  Expert Opin Drug Discov       Date:  2016-10-21       Impact factor: 6.098

Review 3.  Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

Authors:  Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

4.  What can we learn from molecular dynamics simulations for GPCR drug design?

Authors:  Christofer S Tautermann; Daniel Seeliger; Jan M Kriegl
Journal:  Comput Struct Biotechnol J       Date:  2014-12-10       Impact factor: 7.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.